FRANCE LOWERS ORAL CONTRACEPTIVE PRICES
The French authorities have lowered the prices of two oral contraceptive brands, Trinordiol (levonorgestrel/ ethinylestradiol) and Microval (levonorgestrel). Both are made by Wyeth and are newly reimbursable, and prices have been fixed lower than in earlier lists.
The two products were removed from reimbursement in 1990, but they are used by over 70% of the 4 million French women who take oral contraceptives. The new prices, according to the Official Journal, are 10 francs for a set of Microval, down from 23.30 francs, and 49.00 france for three sets of Trinordiol, down from 55.80 francs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze